Table 2.

ongoing studies for recurrent or metastatic cervical cancer.

Trial	Phase	Treatment regimens	Primary end-point
NCT03614949	II	SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites and Atezolizumab 1200 mg intravenously every 3 weeks	ORR
NCT03277482	I	Durvalumab (every 4 weeks for a maximum of 13 doses over 52 weeks) + Tremelimumab (every 4 weeks for a maximum of 4 doses over 16 weeks) + RT	Maximum Tolerated Dose of RT with durvalumab and tremelimumab
NCT05310383	II	Tislelizumab (200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles) plus RT in addition to CT	ORR
NCT04974827	II	Camrelizumab (200mg/3weeks) Combined with concurrent CRT in patients with cervical cancer who had recurrence of the pelvic wall after surgery ± abdominal aortic lymph node metastasis	Complete remission rate
NCT03589339	I	Intratumoral in multiple primary tumors injection of NBTXR3 followed by SABR followed by monotherapy with nivolumab or pembrolizumab	Determination of the Recommended Dose

SBRT, stereotactic body radiation therapy; ORR, overall response rate; RT, radiation therapy; CT, chemotherapy.